Ranbaxy Laboratories Limited (Ranbaxy) announced that the UK Serious Fraud Office's (SFO) prosecution of its UK subsidiary, Ranbaxy (UK) Limited (RUKL), has been quashed by the English Crown Court. The Court also declined an application by the SFO for permission to appeal to the English Court of Appeal, although the SFO retains a right to appeal to the Court of Appeal directly.
Welcoming the decision of the English Crown Court, a company spokesman in a press statement said that Ranbaxy is a responsible company committed to providing high quality generic medicines at affordable prices to its customers and patients throughout the world.
No comments:
Post a Comment